CVA Family Office’s Kronos Bio KRON Stock Holding History

CVA Family Office’s Portfolio KRON Stock Details KRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-200	Closed	-$6K	–	962
2021 Q1	$6K	Sell	200 -200	-50%	-$5.86K	﹤0.01%	596
2020 Q4	$12K	Buy	+400	New	+$12.6K	0.01%	289

Other funds holding KRON

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CVA Family Office's KRON Position: Q2 2021 in Review

CVA Family Office sold out of Kronos Bio (KRON) in Q2 2021, closing a stake of 200 shares — an estimated $6K sold.

CVA Family Office first reported a position in KRON in Q4 2020 and held it in 2 quarters. The position peaked at $12K in Q4 2020. 77 funds tracked by Wall St. Rank hold KRON as of Q2 2021.

CVA Family Office reported no remaining Kronos Bio position as of Q2 2021 after selling out during the quarter.
CVA Family Office sold 200 Kronos Bio shares in Q2 2021, an estimated $6K.
CVA Family Office first reported a position in Kronos Bio in Q4 2020 and held it in 2 quarters.
CVA Family Office's Kronos Bio position peaked at $12K in Q4 2020.
77 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2021.

Based on CVA Family Office's 13F filing for Q2 2021, filed 13 Jul 2021.